Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Crystalys Therapeutics Emerges with $205M to Advance Gout Treatment

Crystalys Therapeutics Emerges with $205M to Advance Gout Treatment

Crystalys Therapeutics, a San Diego-based biotech startup, has launched with a substantial $205 million Series A funding round to develop next-generation therapies for gout. The company's primary focus is on advancing dotinurad, an oral URAT1 blocker already approved in several Asian countries, through global Phase III clinical trials.

NoahAI News9/30/2025
FDA's CDER Director Sparks Controversy Over Surrogate Endpoints in Drug Approvals

FDA's CDER Director Sparks Controversy Over Surrogate Endpoints in Drug Approvals

The pharmaceutical industry is abuzz following controversial comments made by Dr. George Tidmarsh, director of the FDA's Center for Drug Evaluation and Research (CDER), regarding the use of surrogate endpoints in drug approvals. In a now-deleted LinkedIn post, Tidmarsh singled out Aurinia Pharmaceuticals' lupus nephritis drug Lupkynis as an example of the potential shortcomings in relying on such endpoints.

NoahAI News9/30/2025
Barinthus Bio and Clywedog Therapeutics Announce Reverse Merger, Advancing Clinical Assets in Diabetes and Autoimmune Disease

Barinthus Bio and Clywedog Therapeutics Announce Reverse Merger, Advancing Clinical Assets in Diabetes and Autoimmune Disease

In a significant move within the pharmaceutical industry, U.S.-based Barinthus Biotherapeutics and U.K. biotech Clywedog Therapeutics have announced a reverse merger. The combined entity, which will operate under the Clywedog name and trade on the Nasdaq as "CLYD," aims to advance three clinical assets targeting diabetes and autoimmune diseases.

NoahAI News9/30/2025
Rovi Expands Manufacturing Capabilities with $250M BMS Deal and Phoenix Facility Acquisition

Rovi Expands Manufacturing Capabilities with $250M BMS Deal and Phoenix Facility Acquisition

Laboratorios Farmacéuticos Rovi, the Spanish contract development and manufacturing organization (CDMO), has significantly bolstered its production capacity through a landmark deal with Bristol Myers Squibb (BMS). The agreement, valued at $250 million, includes the acquisition of a state-of-the-art manufacturing facility in Phoenix, Arizona, and a five-year manufacturing pact with the pharmaceutical giant.

NoahAI News9/30/2025
AnaptysBio Plans Strategic Split into Two Distinct Companies

AnaptysBio Plans Strategic Split into Two Distinct Companies

AnaptysBio, a prominent player in the biopharmaceutical industry, has announced plans to divide its operations into two separate publicly traded entities. This strategic move, expected to be completed by the end of 2026, aims to maximize value for investors by creating distinct businesses focused on clinical-stage pipeline development and royalty management.

NoahAI News9/30/2025
Opus Genetics Advances Gene Therapy for Rare Eye Disease, Sets Sights on FDA Talks

Opus Genetics Advances Gene Therapy for Rare Eye Disease, Sets Sights on FDA Talks

Opus Genetics, a North Carolina-based biotech company, has made significant strides in its gene therapy program for Leber congenital amaurosis type 5 (LCA5), a rare eye disease affecting approximately 200 people in the United States. The company recently shared promising data from its pediatric trials, paving the way for discussions with the FDA about the program's future.

NoahAI News9/30/2025
Star Therapeutics Secures $125M Funding Boost for Bleeding Disorder Treatment

Star Therapeutics Secures $125M Funding Boost for Bleeding Disorder Treatment

Star Therapeutics has raised $125 million in a Series D funding round to advance its pipeline of bleeding disorder treatments, with a focus on its lead candidate for von Willebrand disease (VWD). The financing, co-led by Sanofi Ventures and Viking Global Investors, will support the company's ongoing Phase 3 trial of VGA039, a potentially transformative therapy for the most common inherited bleeding disorder.

NoahAI News9/30/2025
Pfizer's $4.9B Metsera Acquisition Yields Promising Weight Loss Drug Results

Pfizer's $4.9B Metsera Acquisition Yields Promising Weight Loss Drug Results

Pfizer's recent $4.9 billion acquisition of Metsera is already showing signs of potential success, as the biotech company unveils impressive results for its lead GLP-1 agonist, MET-097i. The injectable candidate, central to Pfizer's obesity drug pipeline expansion, has demonstrated significant weight loss and tolerability in recent clinical trials.

NoahAI News9/30/2025
Sutro Biopharma Announces Second Round of Layoffs Amid Strategic Realignment

Sutro Biopharma Announces Second Round of Layoffs Amid Strategic Realignment

Sutro Biopharma, a biotechnology company specializing in antibody-drug conjugates (ADCs), has announced a significant workforce reduction as part of its ongoing strategic restructuring. This marks the second round of layoffs for the company this year, reflecting the challenges faced by the ADC sector and Sutro's efforts to streamline operations and extend its financial runway.

NoahAI News9/30/2025
Medtech Industry Sees Shift in Funding and M&A Landscape, EY Report Reveals

Medtech Industry Sees Shift in Funding and M&A Landscape, EY Report Reveals

The medical technology sector is experiencing a significant transformation in its funding and merger landscape, according to a recent report by EY. The analysis, covering July 2024 to June 2025, reveals a notable trend of investors concentrating larger sums of money into fewer companies, effectively creating a divide between well-funded "haves" and struggling "have-nots" in the industry.

NoahAI News9/30/2025
FDA Clears EssilorLuxottica's Groundbreaking Eyeglasses to Slow Childhood Myopia Progression

FDA Clears EssilorLuxottica's Groundbreaking Eyeglasses to Slow Childhood Myopia Progression

The U.S. Food and Drug Administration (FDA) has granted a landmark authorization to EssilorLuxottica for its Essilor Stellest eyeglass lenses, designed to slow the progression of myopia in children aged 6 to 12 years. This de novo clearance marks a significant advancement in the treatment of nearsightedness, a rapidly increasing condition among U.S. adolescents that is expected to affect half the world's population by 2050.

NoahAI News9/30/2025
GSK CEO Emma Walmsley's Departure Marks Shift in Pharma Leadership Landscape

GSK CEO Emma Walmsley's Departure Marks Shift in Pharma Leadership Landscape

Emma Walmsley, CEO of GlaxoSmithKline (GSK), is set to step down from her position in January, leaving a significant void in the pharmaceutical industry's top ranks. This departure not only marks the end of Walmsley's tenure at GSK but also highlights the ongoing challenges of gender diversity in leadership roles within the sector.

NoahAI News9/30/2025
«1...414243...67»